Sesterhenn Andreas M, Iwinska-Zelder Joanna, Dalchow Carsten V, Bien Siegfried, Werner Jochen A
Department of Otolaryngology, Head & Neck Surgery, Philipps University, Marburg, Germany.
J Laryngol Otol. 2006 Feb;120(2):117-24. doi: 10.1017/S0022215105003178. Epub 2005 Dec 14.
Acute or subacute haemorrhage is one of the most frightening complications in patients suffering from advanced head and neck cancer. Few articles report experience with superselective endovascular therapy for this purpose. Is endovascular therapy underestimated in the field of palliative head and neck cancer therapy? This study set out to investigate this question.
A review was undertaken of the clinical courses of seven patients (six men, one woman) suffering from incurable, advanced head and neck cancer (four pharyngeal, two laryngeal, one neck) and treated with superselective endovascular strategies as an emergency procedure for acute bleeding.
All patients were successfully treated without evidence of neurological complication. Patients reached a median survival of 20 weeks (range eight-168 weeks). Following endovascular treatment all patients were discharged from the hospital within several days. Three patients survived almost free of symptoms for several weeks and were able to stay at home with their families until their death.
We conclude that in the field of palliative care, superselective endovascular therapy deserves to be considered alongside standard treatment options for the management of acute haemorrhage from advanced head and neck cancer.
急性或亚急性出血是晚期头颈癌患者最可怕的并发症之一。很少有文章报道为此目的进行超选择性血管内治疗的经验。在姑息性头颈癌治疗领域,血管内治疗是否被低估了?本研究旨在探讨这个问题。
回顾了7例(6例男性,1例女性)患有无法治愈的晚期头颈癌(4例咽癌、2例喉癌、1例颈部肿瘤)患者的临床病程,这些患者接受了超选择性血管内治疗作为急性出血的紧急处理措施。
所有患者均成功治疗,无神经并发症迹象。患者的中位生存期为20周(范围8 - 168周)。血管内治疗后,所有患者在数天内出院。3例患者在数周内几乎无症状存活,能够在家中与家人相伴直至死亡。
我们得出结论,在姑息治疗领域,超选择性血管内治疗在晚期头颈癌急性出血的管理中,应与标准治疗方案一同被考虑。